CELL AND GENE THERAPY

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

September 17, 2021

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK
The adoption of CAR T therapies in the UK NHS is a success story, especially seen in
relation to the experience in many other countries. The UK NHS showed itself to be agile,
and responsive to addressing the unique challenges these therapies present, which
facilitated access to patients earlier than in many other countries. (including delivery centre
selection, development of service specifications, collaboration with manufacturers
throughout the preparation phase for adoption, establishment of national multidisciplinary
CAR T team to ensure equity of access and prioritization of resources (where needed)).

Spotlight

TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company based in Taiwan. The company focuses on the discovery, development and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications (limb ischemia and retinopathy). With an executive team that has decades of experience in major multinational pharmaceutical and biotech companies and a high-quality R&D staff, TaiGen is the leading biopharmaceutical company in Asia, and is well positioned to become a major life sciences company worldwide. TaiGen currently has operations in Taiwan, China, and the U.S.

OTHER WHITEPAPERS
news image

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Read More
news image

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More
news image

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More

Spotlight

TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company based in Taiwan. The company focuses on the discovery, development and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications (limb ischemia and retinopathy). With an executive team that has decades of experience in major multinational pharmaceutical and biotech companies and a high-quality R&D staff, TaiGen is the leading biopharmaceutical company in Asia, and is well positioned to become a major life sciences company worldwide. TaiGen currently has operations in Taiwan, China, and the U.S.

Events